Acute myeloid leukemia (AML) is a leading cause of cancer-related deaths in young adults and a highly lethal disease in older adults. Most AML patients do not survive longer than two years.
The Leucegene project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. We envision higher cure rates and longer, disease-free lifespans for AML patients.
NEWS
EVENTS
Researchers
Next-generation sequencing, chemogenomic and precision medicine approaches to cure AML
Health Care Providers
Driving new prognostic tests to the clinic through socio-economic studies and clinician engagement
Patients
Delivering precision medicine for AML to provide cures for this disease
